New GLP1 pill helps patients lose up to 8% of body weight, trial shows

The Guardian - World NewsEN 3 min read 100% complete by Anna Bawden Health and social affairs correspondentFebruary 26, 2026 at 12:39 PM

Read Original Article

AI Summary

medium article 3 min

A clinical trial revealed that Eli Lilly's experimental oral drug, orforglipron, led to greater weight loss (6-8% of body weight) compared to oral semaglutide (4-5%) in adults with type 2 diabetes. Orforglipron, a daily pill targeting GLP-1 receptors like semaglutide, also resulted in lower blood sugar levels. The Achieve-3 trial, involving over 1,500 participants across multiple countries, compared different dosages of both medications over a year. While orforglipron demonstrated superior results, it also had higher discontinuation rates due to gastrointestinal side effects. Orforglipron is currently under review by the FDA and not yet approved in the US, UK, or Europe.

Key Entities & Roles

Key Player Opposition Context

Argentina 30% National Obesity Forum 40% Europe 40% Mounjaro ×250% Tam Fry 50% United Kingdom 50% Wegovy ×370% United States ×470% US Food and Drug Administration 70% Eli Lilly ×290% Semaglutide ×990% Orforglipron ×895%

Keywords

glp-1 100% weight loss 90% orforglipron 90% semaglutide 80% type 2 diabetes 70% oral medication 60% clinical trial 60% blood sugar levels 50% side effects 40%